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Abstract
Objective—To evaluate whether pregnancy-associated hypertension (preeclampsia or gestational 
hypertension), among women with varying degrees of glucose intolerance during pregnancy is 
associated with maternal metabolic syndrome 5-10 years later.
Methods—This was an observational cohort study of women previously enrolled in a treatment 
trial of mild gestational diabetes mellitus or an observational study of lesser degrees of glucose 
intolerance, evaluated 5-10 years following their index pregnancy. At follow-up, women 
underwent anthropometric and blood pressure measurements and analysis of fasting glucose and 
serum lipids.
Results—Eight hundred twenty five women (47% of eligible women from the original study) 
were included in this analysis and evaluated at a median 7 years after their index pregnancy at a 
median age of 35 years. Overall, 239 (29%) had subsequent metabolic syndrome. The frequency 
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of metabolic syndrome and its components was highest in the women who had pregnancy-
associated hypertension and delivered preterm. After adjusting for confounding factors, 
pregnancy-associated hypertension in women who delivered preterm was associated with 
subsequent hypertension (≥130/85 mmHg; relative risk [RR] 3.06, 95% confidence interval [CI] 
1.95-4.80, p<.001), high triglycerides (≥150 mg/dL; RR 1.82, 95% CI 1.06-3.14, p=.03) and 
metabolic syndrome (per the American Heart Association and National Heart Lung and Blood 
Institute Scientific Statement; RR 1.78, 95% CI 1.14-2.78, p=.01), compared with women who 
remained normotensive throughout their index pregnancy and were delivered at term.
Conclusion—Women with varying degrees of glucose intolerance who experienced pregnancy-
associated hypertension and then delivered preterm had a higher frequency of subsequent 
hypertension, high triglycerides and metabolic syndrome 5-10 years later.
Introduction
Several systematic reviews and meta-analyses support the association between pregnancy 
complications and future cardiovascular and metabolic disease in the mother.(1-4) 
Gestational diabetes mellitus (GDM) is a risk factor for future metabolic disease, in 
particular type 2 diabetes,(1,2,5) with its associated cardiovascular complications.(6,7) 
Preeclampsia and gestational hypertension, collectively referred to as pregnancy-associated 
hypertension, have both been shown to be associated with the development of hypertension 
and cardiovascular disease later in life.(2-5,8-16) Several studies suggested that the 
association is strongest with preterm pregnancy-associated hypertension possibly due to its 
earlier onset and/or greater severity.(8,12,17,18) Pregnancy complications may initiate 
vascular damage, alter metabolism, or unmask a woman's risk of future disease via pathways 
common to both pregnancy complications and cardiovascular disease, such as systemic 
inflammation and endothelial dysfunction.(2,5,10,19-22)
The American Heart Association now includes history of preeclampsia, gestational 
hypertension and GDM in their classification of cardiovascular risk factors in women.(23) 
However, much of the data on which this guideline is based were derived from retrospective 
identification of pregnancy complications, linked birth and death registries, and 
administrative data bases. Therefore, the objective of this analysis was to evaluate whether 
pregnancy-associated hypertension is associated with maternal metabolic syndrome at 5-10 
years follow-up in an ethnically-diverse cohort of women with glucose intolerance enrolled 
during pregnancy with rigorously collected data.
Materials and Methods
Women enrolled from October 2002 through mid-November 2007 in the Eunice Kennedy 
Shriver National Institute of Child Health and Human Development Maternal-Fetal 
Medicine Units Network GDM study were evaluated 5-10 years after their index pregnancy 
(February 2012 through September 2013). Details regarding the GDM study have been 
previously described.(24) Briefly, women enrolled in the GDM study were between 24 
weeks 0 days and 30 weeks 6 days of gestation and had an abnormal blood glucose 
concentration (135-200 mg/dl) one hour after a 50 gram glucose loading screen based on 
local laboratory measurement. After an overnight fast the women completed a 3-hour 100 
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gram oral glucose tolerance test, and those with a fasting glucose <95 mg/dl remained 
eligible. Women with an abnormal oral glucose tolerance test consistent with mild GDM 
(two or three oral glucose tolerance test timed measurements that exceeded established 
thresholds: one hour, 180 mg/dl; two hour, 155 mg/dl; and three hour, 140 mg/dl) who 
provided informed consent were randomly assigned to treatment with formal nutritional 
counseling and diet therapy with insulin if required or usual prenatal care. Women with a 
normal oral glucose tolerance test (but had an abnormal screen, and therefore had lesser 
degrees of glucose intolerance) who provided informed consent were enrolled and received 
usual prenatal care. By including this observational cohort of women with lesser degrees of 
glucose intolerance, the patients, their caregivers, and the study staff were unaware of 
whether or not women in the untreated group met the criteria for the diagnosis of mild 
GDM.
Women did not have a prior history of pregestational or gestational diabetes mellitus, renal 
or cardiovascular disease or chronic hypertension, nor did they have preeclampsia at the 
time of enrollment in the original study. The GDM study was approved by the institutional 
review board of all participating centers.
Pregnancy complications, including pregnancy-associated hypertension and gestational age 
at delivery, were collected as part of the original study.(24) Pregnancy-associated 
hypertension included both gestational hypertension and preeclampsia. Gestational 
hypertension was defined as meeting either of the following criteria: 1) diastolic blood 
pressure ≥90 or systolic blood pressure ≥140 on two occasions at least four hours apart; or 
2) one elevated blood pressure subsequently treated with anti-hypertensive medication. 
Preeclampsia was defined as elevation in blood pressure as defined above plus meeting any 
of the following criteria: 1) proteinuria (24-hour urine protein ≥300 mg/24 hours or 24-hour 
urine not done and ≥2+ on dipstick in absence of a urinary tract infection, or 24-hour urine 
not done and protein-creatinine ratio ≥0.35); 2) elevated liver enzyme serum levels (serum 
glutamic oxaloacetic transaminase ≥70 unit/L or lactic acid dehydrogenase ≥600 unit/L); or 
3) thrombocytopenia (platelet count <100,000/mm3); in absence of any other known cause 
of elevated pressures, proteinuria, elevated enzymes, or decreased platelets. All suspected 
cases of pregnancy-associated hypertension were centrally reviewed and adjudicated during 
the original study by two protocol subcommittee physician members. Preterm delivery was 
defined as delivery <37 weeks, 0 days of gestation, with gestational age confirmed by 
ultrasound before enrollment. For the present analysis, women were categorized into one of 
four groups: 1) experienced pregnancy-associated hypertension and delivered preterm; 2) 
experienced pregnancy-associated hypertension and delivered at term; 3) remained 
normotensive throughout their index pregnancy and delivered preterm; 4) remained 
normotensive throughout their index pregnancy and delivered at term (reference group).
The follow-up study was approved by the institutional review board of all participating 
centers and has been previously described.(25) Maternal eligibility included that the patient 
had participated in the original GDM study, she was enrolled at a center still participating in 
the Maternal-Fetal Medicine Units Network at the time of the follow-up study, and her index 
child participated in the follow-up study. Following informed consent, women underwent 
anthropometric and blood pressure measurements, and completed a research staff-
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administered questionnaire about medication use, physical activity, and diet. Weight and 
height were measured using a hospital grade scale and a stationary stadiometer, respectively. 
Waist circumference was measured by trained personnel who received standardized 
anthropometric training, using an AcuFitness MyoTape just above the uppermost lateral 
border of the right ilium of the pelvis,(26) and an average of three measurements was used in 
the analysis. Blood pressure was measured by trained personnel after the participant fasted 
and had not smoked for at least 30 minutes, and was sitting quietly for at least 10 minutes, 
by auscultation using aneroid sphygmomanometer instruments or a hospital grade blood 
pressure/pulse machine. The average of two measurements was used in the analysis. The 
women were queried regarding the number of minutes or hours per week in the last 7 days 
that they engaged in vigorous activity, moderate activity and walking. The diet questions 
queried about the typical number of servings per day or week of various foods, including 
vegetables other than potatoes or corn, dairy, and sweetened beverages. Following a 
minimum 6-hour fast, participants had their blood drawn. Collection, processing and storage 
of specimens were conducted per a standardized approach prior to being shipped on dry ice 
to the Northwest Lipid Metabolism and Diabetes Research Laboratories for lipid panel and 
glucose laboratory measurements. Laboratory analyses were performed the same day as 
sample arrival. Determination of fasting glucose was performed enzymatically using Roche 
reagents on a Roche Module-P autoanalyzer. Lipid panel determination was performed 
enzymatically using Roche reagent on the Roche Modular P autoanalyzer by methods 
standardized to the Centers for Disease Control and Prevention Reference Methods. To 
minimize bias, research staff involved in data collection and laboratory analyses were 
masked to the participant's exposures during the original study. The primary outcome, 
metabolic syndrome, was defined per the American Heart Association / National Heart Lung 
and Blood Institute Scientific Statement(27) as three or more of the following: waist 
circumference >88 cm, triglycerides ≥150 mg/dL, high-density lipoprotein cholesterol <50 
mg/dL, blood pressure ≥130/85 mmHg, or fasting glucose ≥100 mg/dL, or relevant 
treatment for any of these components.
Descriptive analyses used the chi-square test or Fisher's exact test for categorical variables 
and the Kruskal-Wallis test for continuous variables. Continuous variables were assessed to 
evaluate whether they were normally distributed and log-transformed when appropriate. 
Metabolic syndrome (3 or more components) was evaluated as a binomial outcome using 
log-Poisson multiple regression to estimate the relative risk (RR) and 95% confidence 
interval (CI) adjusting for potentially confounding factors. Log-Poisson multiple regression 
was also used to evaluate the binomial components of metabolic syndrome. A post hoc 
analysis using log-Poisson multiple regression evaluated presence of four or more 
components of metabolic syndrome (vs. 0-3 components). The components of metabolic 
syndrome were also evaluated as continuous outcomes using least squares means general 
linear regression. The multivariable models included adjustment for baseline characteristics 
(mild GDM, age, race/ethnicity and body mass index at time of enrollment in the original 
study during the index pregnancy and smoking during the index pregnancy), as well as 
duration of follow-up. Mild GDM treatment was evaluated for potential confounding and 
was shown to not confound observed associations. The models evaluating the continuous 
outcomes were also adjusted for relevant treatments at follow-up. Because smoking is an 
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important cardiovascular risk factor, and because log-Poisson multiple regression allows for 
zero cells (none of the women who experienced pregnancy-associated hypertension and 
delivered preterm smoked during the index pregnancy), the multivariable models included 
adjustment for smoking. However, a sensitivity analysis was conducted in which the 
multivariable models did not include adjustment for smoking. The main analysis did not 
adjust for follow-up characteristics because exposure to pregnancy complications may affect 
subsequent lifestyle, and therefore in the same causal pathway. However, a sensitivity 
analysis was conducted to evaluate whether associations changed after adjusting for follow-
up lifestyle characteristics (i.e., whether there is any indication that lifestyle explained some 
of the observed associations), specifically vegetable consumption and vigorous physical 
activity. A third sensitivity analysis adjusted for pre-pregnancy body mass index rather than 
pregnancy body mass index. Pre-pregnancy body mass index was not used in the main 
analysis because it was not measured in a standardized way, included patient self-report, and 
was missing in 66 women. A fourth sensitivity analysis excluded 19 women with pre-
pregnancy body mass index ≥40 as an assumption that they may have had metabolic 
syndrome at baseline. SAS software version 9.2 was used for the analyses. All tests were 
two-tailed and p<.05 was used to define statistical significance. No imputation for missing 
data was performed.
Results
This analysis included 825 women (47% of eligible women from the original study) who 
participated in the follow-up study and were not pregnant at the time of follow-up (Figure 
1). The maternal baseline characteristics were generally similar between women who did 
and did not participate in the follow-up study, although some differences were observed 
(Appendix 2, available online at http://links.lww.com/xxx). Most notably, a higher 
percentage of the non-Hispanic white women participated in the follow-up study. The 
percent of women who experienced pregnancy-associated hypertension and/or were 
delivered preterm was similar between participants and non-participants (Appendix 2, http://
links.lww.com/xxx).
Among the 825 women included in this analysis, 20 (2%) developed pregnancy-associated 
hypertension during the index pregnancy and delivered preterm (40% gestational 
hypertension; 60% preeclampsia), 64 (8%) developed pregnancy-associated hypertension 
and delivered at term (70% gestational hypertension; 30% preeclampsia), 48 (6%) remained 
normotensive throughout their index pregnancy and delivered preterm, and 693 (84%) 
remained normotensive throughout their index pregnancy and delivered at term. Among 
those who were delivered preterm, spontaneous delivery (31 women experienced preterm 
spontaneous labor and 6 women were induced after experiencing preterm premature rupture 
of membranes) occurred in 71% of those who remained normotensive throughout their index 
pregnancy and 15% of those who experienced pregnancy-associated hypertension.
The follow-up evaluation occurred at a median 7 (interquartile range 6-8) years after the 
index pregnancy at a median age of 35 (interquartile range 32-40) years. Fifty-six percent of 
the women included in this analysis were Hispanic, 31% non-Hispanic white, 10% non-
Hispanic black and 3% other. Body mass index was highest in the women who experienced 
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pregnancy-associated hypertension and delivered preterm (Table 1). Among the women with 
preterm birth, the median gestational age at birth was 36.1 weeks in the women with 
pregnancy-associated hypertension and 35.9 in the women with normotensive pregnancies.
Subsequent high waist circumference (>88 cm) and low high-density lipoprotein cholesterol 
(<50 mg/dL) were observed in the majority of the women (63% and 57%, respectively). The 
frequency of each component of metabolic syndrome was highest in the women who 
experienced pregnancy-associated hypertension and delivered preterm (Table 2). When 
evaluating components of metabolic syndrome, and after adjusting for baseline confounding 
factors, pregnancy-associated hypertension was significantly associated with subsequent 
hypertension in women who were delivered preterm (RR 3.06, 95% CI 1.95-4.80, p<.001) 
and at term (RR 1.76, 95% CI 1.22-2.53, p=.002) (Table 2), and correspondingly 
significantly higher adjusted mean measures of systolic and diastolic blood pressures (Figure 
2, Panels A and B), compared with women who remained normotensive and were delivered 
at term. Pregnancy-associated hypertension in women who delivered preterm was 
significantly associated with subsequent high triglycerides (RR 1.82, 95% CI 1.06-3.14, p=.
03)(Table 2), and correspondingly significantly higher adjusted mean measure of 
triglycerides (Figure 2, Panel C). Preterm delivery in women who remained normotensive 
throughout their index pregnancy was not associated with any of the components of 
metabolic syndrome.
Overall, 239 (29%) had metabolic syndrome; 33% in those with mild GDM and 24% in 
those with lesser degrees of glucose intolerance. The frequency of metabolic syndrome was 
similar between the women who experienced gestational hypertension and the women who 
experienced preeclampsia, 43% and 45%, respectively. The frequency of metabolic 
syndrome ranged from 21% in the women who remained normotensive throughout their 
index pregnancy and delivered preterm to 70% in the women who experienced pregnancy-
associated hypertension and delivered preterm (Table 2). Furthermore, the percent of women 
experiencing 4 or more metabolic syndrome components was highest in the women who 
experienced pregnancy-associated hypertension and then delivered preterm (30%, compared 
with 8% in those who remained normotensive and delivered at term; p<.001)(Table 2). After 
adjusting for baseline confounding factors, pregnancy-associated hypertension in women 
who delivered preterm was significantly associated with subsequent metabolic syndrome (3 
or more components) (RR 1.78, 95% CI 1.14-2.78, p=.01) (Table 2), compared with women 
who remained normotensive and delivered at term. Pregnancy-associated hypertension was 
significantly associated with experiencing 4 or more (vs. 0-3) metabolic syndrome 
components in women who were delivered preterm (RR 3.00, 95% CI 1.74-5.18, p<.001) 
and at term (RR 1.64, 95% CI 1.05-2.58, p=.03) (Table 2).
The associations remained consistent between models with and without adjustment for 
smoking, adjustment for lifestyle characteristics at the time of follow-up (diet and physical 
activity), adjustment for pre-pregnancy body mass index rather than pregnancy body mass 
index, or adjustment for pre-pregnancy body mass index and excluding women with a pre-
pregnancy body mass index ≥40 (Appendix 3, available online at http://links.lww.com/xxx). 
We observed several modifiable risk factors significantly associated with metabolic 
syndrome: enrollment smoking (OR 1.71, 95%CI 1.18-2.47, p=.005); enrollment body mass 
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index (OR 14.67, 95%CI 8.15-26.41 per unit increase in log body mass index, p<.001); and 
follow-up vegetable intake (OR 0.77, 95%CI 0.67-0.87 per unit increase in daily servings, 
p<.001).
Discussion
In an obstetric population without known pre-existing conditions, but with varying degrees 
of glucose intolerance, women who experienced pregnancy-associated hypertension and 
then delivered preterm had a significantly higher likelihood of experiencing hypertension, 
high triglycerides, metabolic syndrome (3 or more components) and 4 or more metabolic 
syndrome components 5-10 years later. Furthermore, although the magnitude of the 
association was weaker, pregnancy-associated hypertension in women who were delivered 
at term had a significantly higher likelihood of subsequent hypertension and experiencing 4 
or more metabolic syndrome components.
Studies performed outside of the United States, in primarily white European populations, 
have also observed an association between pregnancy-associated hypertension and 
subsequent metabolic syndrome. In a United Kingdom prospective population-based study 
of 3,416 women followed up 18 years after delivery, gestational hypertension was 
associated with higher waist circumference, higher blood pressure, higher triglycerides and 
lower high-density lipoprotein cholesterol, and preeclampsia was associated with higher 
blood pressure and higher glucose.(14) In a study of 15,065 Norwegian women, with 
retrospectively linked registry delivery data, followed prospectively 16.5 years after 
pregnancy, both gestational hypertension and preeclampsia were associated with high 
triglycerides, low high-density lipoprotein cholesterol and high systolic blood pressure. (13) 
In a time frame of 7.8 years after delivery, 168 nulliparous Canadian women who had either 
gestational hypertension or preeclampsia were followed prospectively, and had a higher 
frequency of metabolic syndrome, high waist circumference, low high-density lipoprotein 
cholesterol and high blood pressure, compared with 168 retrospectively matched 
controls.(11) Also, the metabolic syndrome risk profile was similar between the women with 
gestational hypertension and the women with preeclampsia. In another Canadian study of 
women prospectively followed after delivery, preeclampsia was associated with metabolic 
syndrome at the one-year (n=99 preeclampsia, n=118 controls) and three-year (n=73 
preeclampsia, n=47 controls) follow-ups.(28) In a study from The Netherlands, 306 women 
with either gestational hypertension or preeclampsia at term who participated in a pregnancy 
trial were prospectively followed up 2.5 years after delivery, and found to have a higher 
frequency of metabolic syndrome and high blood pressure compared with 99 retrospectively 
matched normotensive term controls.(15)
Our study provided a unique opportunity to prospectively evaluate the association between 
pregnancy-associated hypertension and subsequent metabolic syndrome in an ethnically 
diverse U.S. population. A limitation of this study, however, was the relatively modest 
sample size with only 20 women who experienced pregnancy-associated hypertension and 
then delivered preterm. We therefore were not able to evaluate gestational hypertension and 
preeclampsia separately. However, the frequency of metabolic syndrome was similar in 
these groups, also observed by Forest et al(11) who suggested that gestational hypertension 
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and preeclampsia may have similar long-term risks. Another limitation is that although the 
women did not have known preexisting clinically-diagnosed conditions, it is uncertain 
whether some of the women may have met criteria for metabolic syndrome before the index 
pregnancy but were not diagnosed. Even so, pregnancy may unmask not only future health 
but also existing preclinical conditions that may not be routinely screened for in women of 
reproductive age. It should also be noted that women with chronic hypertension or 
preeclampsia at the time of enrolment were excluded from the original study, so none had 
the hypertension component at baseline. An additional limitation is that a higher percentage 
of the non-Hispanic white women participated in the follow-up study. Despite this, 56% of 
the women included in this analysis were Hispanic. With regards to generalizability, 
although our study included women with mild GDM or lesser degrees of glucose 
intolerance, our results are consistent with studies in other obstetric cohorts.
There are numerous strengths of this study. Women were enrolled during pregnancy and 
therefore pregnancy complications were prospectively collected and defined in a 
standardized research setting, rather than relying on vital statistics or administrative data 
sets. Cases of pregnancy-associated hypertension were reviewed and adjudicated and 
gestational age at delivery was confirmed by ultrasound. Likewise, data at the follow-up 
visit were prospectively collected using rigorous definitions, trained research staff 
performed anthropometric measurements, and lipids and glucose were measured at a central 
laboratory. Furthermore, our analysis controlled for several potentially confounding factors, 
including baseline cardiovascular-related risk factors, and we observed several modifiable 
risk factors associated with metabolic syndrome (smoking, higher body mass index and 
lower vegetable consumption).
In conclusion, our results provide further support that women who experience pregnancy-
associated hypertension, particularly if then delivered preterm, are at an especially higher 
risk of developing metabolic syndrome. Moreover, physicians should carefully monitor and 
counsel these women concerning their long-term health risks.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Enrollment, follow-up, and adverse pregnancy exposure status of the study participants.
Rice et al. Page 11
Obstet Gynecol. Author manuscript; available in PMC 2017 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. 
Mean adjusted* cardiometabolic measures (components of the metabolic syndrome at 
follow-up) according to adverse pregnancy exposure status during the index pregnancy. 
Systolic blood pressure (A); diastolic blood pressure (B); triglycerides (C); high-density 
lipoprotein (HDL) cholesterol (D); blood glucose (E); waist circumference (F). *Adjusted 
for baseline mild gestational diabetes mellitus, age, race or ethnicity, smoking, log body 
mass index, and duration of follow-up. The models were also adjusted for relevant 
treatments at follow-up. †Log values back transformed.
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